glp 1 peer reviewed articles Discovery of GLP-1–Based Drugs for the Treatment of Obesity Compare GLP-1 Options | Ozempic

in kidney-transplant recipients, RCT data suggest maintaining 25(OH)D 30 ng/mL may optimize bone endpoints (bone mineral density, BMD/fracture)

Approved Medical Uses: Prevention & Treatment of B12 Deficiency: Corrects low B12 due to poor nutrition, GI disorders, or malabsorption

This pattern reflects how GLP-1 receptor agonists work: they suppress appetite and slow stomach emptying only while the medication remains in your system

JARDIANCE is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease [see Clinical Studies (14.5)]

Consult a health care practitioner prior to use if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of other serious conditions)

: